Finerenone

CHEMBL2181927 Phase 4 已批准 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
378.4 g/mol
LogP
2.4
Phase
4

This medication blocks a hormone receptor called the mineralocorticoid receptor, reducing inflammation and scarring in the heart and kidneys. It is used to slow the progression of chronic kidney disease in adults with type 2 diabetes and to reduce the risk of heart failure.

分子量

378.4000 g/mol

LogP

2.40

TPSA

110.00 Ų

Lipinski 五规则

符合

治疗领域

作用机制

Provides an essential mineral element required for numerous enzymatic reactions, structural proteins, and physiological processes. Supplementation addresses deficiency states.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Provides an essential mineral element required for numerous enzymatic reactions, structural proteins, and physiological processes. Supplementation addresses deficiency states.

二维结构

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCOc1ncc(C)c2c1[C@H](c1ccc(C#N)cc1OC)C(C(N)=O)=C(C)N2

InChI

InChI=1S/C21H22N4O3/c1-5-28-21-18-17(14-7-6-13(9-22)8-15(14)27-4)16(20(23)26)12(3)25-19(18)11(2)10-24-21/h6-8,10,17,25H,5H2,1-4H3,(H2,23,26)/t17-/m1/s1

Molecular Formula

C21H22N4O3

HBD / HBA

2 / 6

可旋转键数

5

重原子数

28

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

This medication blocks a hormone receptor called the mineralocorticoid receptor, reducing inflammation and scarring in the heart and kidneys. It is used to slow the progression of chronic kidney disease in adults with type 2 diabetes and to reduce the risk of heart failure.

Provides an essential mineral element required for numerous enzymatic reactions, structural proteins, and physiological processes. Supplementation addresses deficiency states.

Yes, Finerenone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2181927. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 60150535. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.